ADC manufacturing will likely stay with established CDMOs due to high barrier to market entry

An­ti­body-drug con­ju­gate (AD­Cs) man­u­fac­tur­ing is like­ly to re­main among CD­MOs al­ready mak­ing them due to de­mand­ing mar­ket en­try re­quire­ments, ex­ec­u­tives in the ADC space said. ADC tox­i­c­i­ty re­quires ex­tra care in pro­duc­tion, with staff train­ing and equip­ment need­ed be­yond tra­di­tion­al man­u­fac­tur­ing for chemother­a­pies and an­ti­bod­ies, they added.

“CD­MOs of all sizes prob­a­bly see the cur­rent mar­ket po­ten­tial for de­vel­op­ment and man­u­fac­ture of AD­Cs, but the abil­i­ty to en­ter the space ef­fi­cient­ly is lim­it­ed for many,” added Roger Lias, CCO at Au­ri­gene Phar­ma­ceu­ti­cal Ser­vices, a CD­MO with ADC man­u­fac­tur­ing abil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.